Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410577 | 1.00 | SCN4A (0.51) | SCN4ASLC6A2SLC6A4GRIN2DGRIN3B | |
| SCHEMBL3282320 | 0.81 | PNMT (0.44) | SCN4ASLC6A2SLC6A4 | |
| SCHEMBL6748010 | 0.80 | TAAR1 (0.45) | SCN4ASLC6A2SLC6A4TAAR1 | |
| SCHEMBL12706135 | 0.80 | TAAR1 (0.45) | SCN4ASLC6A2SLC6A4TAAR1 | |
| SCHEMBL12706026 | 0.80 | TAAR1 (0.45) | SCN4ASLC6A2SLC6A4TAAR1 | |
| SCHEMBL4981770 | 0.78 | TACR1 (0.59) | SCN4A | |
| SCHEMBL9054723 | 0.78 | GRIN2D (0.47) | SCN4AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6547026 | 0.78 | SLC6A2 (0.49) | SLC6A2SLC6A4TAAR1 | |
| Ortetamine SCHEMBL209899 | 0.77 | TAAR1 (0.52) | SLC6A2SLC6A4TAAR1 | |
| Ortetamine SCHEMBL3460028 | 0.77 | TAAR1 (0.52) | SLC6A2SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360160-B1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO CO LTD (JP) | 2013-07-24 | — | — | EP | claimed |
| EP-2360160-A1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-24 | — | — | EP | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7087778-B2 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | claimed |
| US-20050027119-A1 | Process for producing benzoxazine derivative and production intermediate thereof | DAIICHI PHARMACEUTICAL CO., LTD. | 2005-02-03 | — | — | US | claimed |
| EP-1211254-A1 | PROCESS FOR THE PREPARATION OF BENZOXAZINE DERIVATIVES AND INTERMEDIATES THEREFOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | claimed |
| EP-0208948-A2 | A method for optical resolution of phenylacetic acid derivative | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-01-21 | — | — | EP | claimed |
| US-9969694-B2 | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160272592-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-1211254-B1 | Process for the preparation of benzoxazine derivatives and intermediates therefor | DAIICHI SANKYO CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-2284174-B1 | Intermediates for the preparation of benzoxazine derivatives and process for their preparation | DAIICHI SANKYO CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2360160-B1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| EP-0092194-B1 | METHOD OF OBTAINING OPTICALLY ACTIVE HALF ESTERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0220435-A1 | A method for preparing optically active half esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-05-06 | — | — | EP | disclosed |
| EP-0093511-B1 | METHOD FOR PRODUCING AND OPTICALLY ACTIVE 2,2-DIMETHYLCYCLOPROPANECARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-09-24 | — | — | EP | disclosed |
| EP-0060466-B1 | METHOD FOR OPTICAL RESOLUTION OF 2-(4-CHLOROPHENYL)-3-METHYL-BUTANOIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-07-11 | — | — | EP | disclosed |
| EP-0092194-A1 | Method of obtaining optically active half esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-10-26 | — | — | EP | disclosed |
| US-4246424-A | IN PRESENCE OF ALKALI METAL AND POLYCYCLIC AROMATIC HYDROCARBON | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-01-20 | — | — | US | disclosed |
| US-4158016-A | CONTACTING WITH AN ALKALI METAL POLYCYCLIC AROMATIC HYDROCARBON CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027119-A1 | Process for producing benzoxazine derivative and production intermediate thereof | CYP4Z1, COASY, VAT1 | SCN4A 2534/4885SLC6A2 3350/4885SLC6A4 3506/4885 |
| US-20160272592-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, CNKSR1, CHUK | SCN4A 1475/4885SLC6A2 1974/4885SLC6A4 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.